1. Home
  2. TWST vs ERAS Comparison

TWST vs ERAS Comparison

Compare TWST & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$110.22

Market Cap

7.4B

Sector

Health Care

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

SELL

Current Price

$13.80

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TWST
ERAS
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
6.3B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
TWST
ERAS
Price
$110.22
$13.80
Analyst Decision
Buy
Buy
Analyst Count
13
9
Target Price
★ $128.92
$24.11
AVG Volume (30 Days)
2.3M
★ 4.8M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 36.23
EPS
N/A
★ N/A
Revenue
★ $459,433,000.00
N/A
Revenue This Year
$21.02
N/A
Revenue Next Year
$18.75
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 22.00
N/A
52 Week Low
$25.23
$2.75
52 Week High
$219.71
$24.28

Technical Indicators

Market Signals
Indicator
TWST
ERAS
Relative Strength Index (RSI) 38.28 43.56
Support Level $79.90 $13.18
Resistance Level $155.44 $15.71
Average True Range (ATR) 15.07 1.31
MACD -3.22 0.02
Stochastic Oscillator 18.52 18.09

Price Performance

Historical Comparison
TWST
ERAS

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: